Expanding Medication-Assisted Therapies in Central Asia

Study acronym: ExMAT CA
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 31, 2026 → Dec 31, 2027
See other at-risk trials from Yale University

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027
    • Eligibility criteria expanded, about 23 words
    • Study description expanded, about 3 words
  2. Minor Re-verified, no change to tracked fieldsv6
  3. Minor Study sites revised (4)
    • Collaborators revised (4)
    v5
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 4 of 4 sites
    v4
  5. Notable Start date: Jun 1, 2023 to Aug 7, 2023
    • Study completion date: Dec 31, 2027 to Dec 31, 2026
    v3
  6. Notable Start date: Jan 1, 2023 to Jun 1, 2023v2
  7. Minor Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
490 trials monitored
See 31 trials at risk
Central Asia (CA) represents the most rapidly growing HIV epidemic region worldwide, concentrated in people who inject drugs (PWID) and their sexual partners, and scaling up opioid agonist therapies (OAT) in this region is the most cost-effective strategy to prevent new HIV infections, and more effective when combined with antiretroviral therapy (ART). The investigators propose to use the Network for the Improvement of Addiction Treatment (NIATx) implementation strategy to scale-up OAT in three diverse Central Asian countries (Kazakhstan, Kyrgyzstan, Tajikistan) and guided by the Exploration-Planning-Implementation-Sustainment (EPIS) framework. Understanding the trajectories of implementation and scale-up in this context may emerge through creating communities of practice, especially when cohesion and competence evolves, and may guide other healthcare delivery challenges in the region (e.g., HIV, TB); as well as build important regional expertise and understanding implementation trajectories should help support OAT program sustainability.
Trial Details
NCT Number NCT05579470
Lead Sponsor Yale University
Collaborators: Den Sooluk Nuru, Institute for International Health and Education, Global Health Research Center of Central Asia, National Institute on Drug Abuse (NIDA)
Conditions
(from sponsor)
Opioid Use Disorder
Related terms Opioid-Related Disorders
Enrollment 900 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov